Journal article
Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease: A Report of 2 Patient Cases
JIM - high impact case reports, Vol.4(4), pp.2324709616674316-2324709616674316
10/2016
DOI: 10.1177/2324709616674316
PMID: 27826593
Abstract
Historically, metastatic melanoma was uniformly and rapidly lethal, and treatment options were limited. In recent years, however, checkpoint inhibitors have emerged as an accepted standard treatment for patients with advanced melanoma. In clinical trials, these agents have been largely well tolerated and have the potential to result in durable responses. Importantly though, one must recognize the unique side effect profile of these therapies, which can trigger or exacerbate underlying autoimmune disease. Whether this autoimmune activation is associated with a clinical response to therapy has been debated, and while not definitive, there is evidence in the literature of a possible association. The 2 cases presented describe this autoimmune phenomenon, along with a review of the existing literature on the relationship between response to immunotherapy and autoimmune side effects.
Details
- Title: Subtitle
- Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease: A Report of 2 Patient Cases
- Creators
- Sneha D Phadke - Department of Internal Medicine, Divison of Hematology/Oncology, University of Iowa Hospitals & Clinics, Iowa City, IA, USARamez Ghabour - Department of Internal Medicine, University of Iowa Hospitals & Clinics, Iowa City, IA, USABrian L Swick - Department of Dermatology, University of Iowa Hospitals & Clinics, Iowa City, IA, USAAndrea Swenson - Department of Neurology, University of Iowa Hospitals & Clinics, Iowa City, IA, USAMohammed Milhem - Department of Internal Medicine, Divison of Hematology/Oncology, University of Iowa Hospitals & Clinics, Iowa City, IA, USAYousef Zakharia - Department of Internal Medicine, Divison of Hematology/Oncology, University of Iowa Hospitals & Clinics, Iowa City, IA, USA
- Resource Type
- Journal article
- Publication Details
- JIM - high impact case reports, Vol.4(4), pp.2324709616674316-2324709616674316
- DOI
- 10.1177/2324709616674316
- PMID
- 27826593
- NLM abbreviation
- J Investig Med High Impact Case Rep
- ISSN
- 2324-7096
- eISSN
- 2324-7096
- Publisher
- SAGE Publications; Sage CA: Los Angeles, CA
- Language
- English
- Date published
- 10/2016
- Academic Unit
- Dermatology; Neurology; Hematology, Oncology, and Blood & Marrow Transplantation; Pathology; Orthopedics and Rehabilitation; Internal Medicine
- Record Identifier
- 9984025481502771
Metrics
18 Record Views